PharmaCyte Biotech Inc Total Liabilities
PharmaCyte Biotech Inc total liabilities. Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has total liabilities worth $11.77 Million USD as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PharmaCyte Biotech Inc (PMCB) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PharmaCyte Biotech Inc (2002–2026)
Total liabilities of PharmaCyte Biotech Inc from 2002 to 2026. This chart illustrates how PharmaCyte Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore PharmaCyte Biotech Inc (PMCB) investment intensity to see how much of total assets are deployed in long-term investments.
PharmaCyte Biotech Inc Competitors by Total Liabilities
The table below lists competitors of PharmaCyte Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Highway Holdings Limited
NASDAQ:HIHO
|
USA | $1.87 Million |
|
ZhongDe Waste Technology AG
F:ZEF
|
Germany | €18.24 Million |
|
Arcadia Minerals Ltd
AU:AM7
|
Australia | AU$865.44K |
|
Ranplan Group
ST:RPLAN
|
Sweden | Skr14.91 Million |
|
Burley Minerals Ltd
AU:BUR
|
Australia | AU$168.12K |
|
Indus Gas Ltd
F:59Q
|
Germany | €1.06 Billion |
|
Yu Group PLC
LSE:YU
|
UK | GBX211.50 Million |
|
APC Minerals Ltd
AU:APC
|
Australia | AU$422.25K |
Liability Composition Analysis (2002–2026)
This chart breaks down PharmaCyte Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of PharmaCyte Biotech Inc.
Liquidity & Leverage Metrics
PharmaCyte Biotech Inc Total Liabilities Ratios Explained
PharmaCyte Biotech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 45.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaCyte Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaCyte Biotech Inc (2002–2026)
The table below shows the annual total liabilities of PharmaCyte Biotech Inc from 2002 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-04-30 | $11.77 Million | +259.21% |
| 2025-04-30 | $3.28 Million | -83.93% |
| 2024-04-30 | $20.39 Million | +3375.95% |
| 2023-04-30 | $586.58K | -16.72% |
| 2022-04-30 | $704.37K | -2.82% |
| 2021-04-30 | $724.78K | -32.75% |
| 2020-04-30 | $1.08 Million | +45.07% |
| 2019-04-30 | $742.85K | +15.32% |
| 2018-04-30 | $644.17K | +11.02% |
| 2017-04-30 | $580.25K | -9.00% |
| 2016-04-30 | $637.64K | -68.31% |
| 2015-04-30 | $2.01 Million | +438.56% |
| 2014-04-30 | $373.67K | -90.16% |
| 2013-04-30 | $3.80 Million | +0.29% |
| 2012-04-30 | $3.79 Million | -4.59% |
| 2011-04-30 | $3.97 Million | +25.88% |
| 2010-04-30 | $3.15 Million | +8.14% |
| 2009-04-30 | $2.92 Million | +1515.02% |
| 2008-04-30 | $180.56K | +51.98% |
| 2007-04-30 | $118.81K | -83.59% |
| 2006-04-30 | $723.89K | -55.63% |
| 2005-04-30 | $1.63 Million | +395.68% |
| 2004-04-30 | $329.13K | +12934.97% |
| 2003-04-30 | $2.52K | -67.85% |
| 2002-04-30 | $7.86K | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also devel… Read more